Propanc Biopharma, Inc. Common Stock

Propanc Biopharma issued a comparative analysis of its preclinical lead candidate PRP against clinical data from Erasca's pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma. In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP achieved greater than 90% mean tumor-growth inhibition versus vehicle controls and extended median overall survival more than 2.5-fold, with reduced liver and peritoneal metastatic burden, decreased cancer-associated fibroblast activity, less fibrosis, and re-sensitization of chemo-resistant cells to gemcitabine/nab-paclitaxel. PRP, a fixed-ratio 1:6 combination of the pancreatic proenzymes trypsinogen and chymotrypsinogen, does not inhibit RAS but promotes differentiation, reverses epithelial-mesenchymal transition, depletes cancer stem cells, and remodels the tumor microenvironment; it holds FDA Orphan Drug Designation for pancreatic cancer and is not restricted to a specific RAS genotype. Erasca's ERAS-0015, an oral pan-RAS molecular glue, has shown unconfirmed overall response rates of 40% at 16–32 mg once daily and 42% at 24–32 mg in second-line KRAS G12X PDAC, with a July 2026 update reporting 57% unconfirmed 8-week ORR at the 32 mg recommended expansion dose, and received FDA Fast Track designation for metastatic pancreatic adenocarcinoma on August 24, 2026. Propanc said it is progressing GMP manufacturing and pharmacokinetics assay validation toward a planned Phase 1b First-in-Human study of approximately 40 to 50 patients with advanced solid tumors, with first patient dosing targeted for February 2027.

Propanc Biopharma has signed a Memorandum of Understanding with Avance Clinical to collaborate on the clinical delivery of a planned Phase 1b First-in-Human trial for PRP, its lead investigational candidate for advanced solid tumors. The study will evaluate safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity in patients with advanced cancer. Avance Clinical brings more than 30 years of experience in early-phase oncology trials and offers advantages such as rapid ethics approval and significant R&D tax rebates in Australia. Propanc, headquartered in Melbourne since 2007, aims to capitalize on these benefits. CEO James Nathanielsz called the MOU an important milestone toward clinical evaluation, citing PRP's unique mechanism of action, low toxicity, and good tolerability for patients with limited treatment options.